Whalesbook
Bhai, latest update yeh hai ki bade private hospitals government ki health schemes se apna involvement strategically kam kar rahe hain. Iss strategic move ka main reason hai financial pressure, jiske chalte woh apni profit margins protect karna chahte hain. Basically, cash flow ko stable rakhne ke liye yeh sab ho raha hai.
Paiso ka chakkar aur revenue par asar
Mamla yeh hai ki govt schemes se hospitals ki total revenue ka lagbhag 25% aata hai. Lekin ab analysts bol rahe hain ki FY27 ke Q1 tak yeh share 3-5% aur kam ho sakta hai. Iska reason hospitals ka selective participation hai. Jaise Max Healthcare ne bataya hai ki CGHS scheme se unka ₹200 crore ka revenue impact hua hai, aur abhi bhi ₹140 crore ki financial strain chal rahi hai. Sabse badi problem payment mein deri aur low reimbursement rates hain, jis se profit kam ho jata hai aur paisa wapas aane mein bahut time lagta hai.
Stock market mein kya chal raha hai?
Issi financial pressure ki wajah se alag-alag hospitals ke stock valuations mein bhi fark dikh raha hai. May 2026 tak Max Healthcare ki market cap lagbhag ₹98,871 crore thi, Fortis Healthcare ki ₹71,687 crore, Narayana Health ki ₹36,020 crore, aur HealthCare Global Enterprises (HCG) ki ₹8,612 crore thi. Apollo Hospitals, jinki market cap ₹111,253 crore hai, unhone bola hai ki govt schemes unki revenue ka chhota hissa hain, aur unki 83% inpatient revenue private insurance aur self-paying patients se aa rahi hai.
Scheme ki problems ke beech sector ka growth
Yeh sab tab ho raha hai jab India ka healthcare sector bohot fast grow kar raha hai aur 2030 tak $700 billion ka ho sakta hai. Aam log bhi health par zyada kharch kar rahe hain aur insurance penetration bhi badh rahi hai. Nifty Healthcare Index bhi market se achha perform kar raha hai. Par hospitals 2020 se hi govt schemes mein payment delays aur kam reimbursement ko lekar pareshan hain, yeh problem pichhle saal se aur badh gayi hai.
Rates badhe, par tension abhi bhi hai
October 2025 mein CGHS rates ko update kiya gaya tha, jisme hospital ke accreditation aur location ke hisab se rates badhaaye gaye the, average 25-30% ka increase hua tha. Yeh update thoda relief de sakta hai, par payment mein deri wali problem abhi bhi bani hui hai. Pehle bhi private hospitals Ayushman Bharat jaise schemes se isi wajah se door ho jate the. HCG ka P/E ratio 400 se upar hai, par return on equity sirf 0.12% hai, jo dikhata hai ki agar scheme se related financial issues rahe to profitability par sawaal uth sakta hai.
Future strategy aur outlook
Rates badhne ke baad bhi, govt schemes wale hospitals ke liye challenges kam nahi hue hain. PMJAY, MJPJAY, RSBY jaise schemes mein historical payment delays abhi bhi cash flow ko affect kar sakte hain, khaas kar chote players ke liye. Regulatory oversight kam hona aur hospitals ka cities mein concentrated hona bhi ek issue hai. Yeh fact ki sirf 20% private hospitals PMJAY scheme mein hain, kyunki woh financially viable nahi lagti, yeh unki operational difficulties ko show karta hai. Narayana Health ne apne northern region mein scheme volumes ko cap karne ka jo decision liya hai, woh financial risks ko manage karne ka ek smart tareeka hai. Govt schemes se revenue mein jo kami aane ki ummeed hai, woh hospitals ke strategic shift ko dikhati hai. CGHS rate update accha hai, par uski poori fayda timely payments par depend karega. Healthcare market grow karegi, par hospitals financially stable rehne ke liye private insurance aur self-paying patients ko priority dete rahenge.